Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.

September 18, 2015 at 3:34 pm

Drug Des Devel Ther. 2015 Jun 4;9:2919-25.

Skalweit MJ1.

1Department of Medicine, Louis Stokes Cleveland Department of Veterans Affairs and Case Western Reserve University School of Medicine, Cleveland, OH, USA ; Department of Biochemistry, Louis Stokes Cleveland Department of Veterans Affairs and Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Abstract

Drug-resistant pathogens have gained a foothold especially in the most vulnerable patient populations, hospitalized and immunocompromised individuals.

Furthermore, extended-spectrum β-lactamase and carbapenemase-producing organisms are finding their way even into the community, with patients presenting to the hospital with established colonization and infection with resistant Enterobacteriaceae in particular.

Recently, a novel antipseudomonal cephalosporin in combination with an established Class A β-lactamase inhibitor, ceftolozane/tazobactam has been approved by the FDA for use in the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Ceftolozane is a uniquely potent antipseudomonal cephalosporin because of its high affinity for the penicillin-binding proteins of Pseudomonas aeruginosa, its low affinity for the intrinsic Class C β-lactamases of P. aeruginosa, its ability to enter P. aeruginosa through the outer membrane without the utilization of OprD protein, and the fact that it is not a substrate of the often upregulated MexAB/OprM efflux system of P. aeruginosa.

The biological chemistry, pharmacokinetics/pharmacodynamics, microbiologic spectrum, and clinical trials that led to the approval of ceftolozane is reviewed.

A discussion regarding its potential role in the treatment of complicated intra-abdominal infections and other infectious disease syndromes associated with drug-resistant pathogens follows.

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461093/pdf/dddt-9-2919.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Health Care-Associated Infections, HIC no SIDA, Infecciones en neutropenicos, Infecciones en seniles, Infecciones intraabdominales, Infecciones nosocomiales, Metodos diagnosticos, Resistencia bacteriana, Sepsis. Tags: .

Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia


Calendar

September 2015
M T W T F S S
« Aug   Oct »
 123456
78910111213
14151617181920
21222324252627
282930  

Most Recent Posts


%d bloggers like this: